Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by AVEO Oncology

AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology to Host Key Opinion Leader Webinar on Ficlatuzumab in Head and Neck Squamous Cell Carcinoma
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology to Present at the Jefferies 2021 Virtual Healthcare Conference
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology Announces Presentation of Long-Term Efficacy Follow Up, Additional Tolerability Data from the Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Relapsed or Refractory Renal Cell Carcinoma
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology Announces Positive Results from Randomized Phase 2 Study of Ficlatuzumab in Combination with Cetuximab in Pan-Refractory, Metastatic HNSCC
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
From AVEO Oncology
Via Business Wire
Tickers AVEO
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
From AVEO Oncology
Via Business Wire
Tickers AVEO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.